{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:04:48Z","timestamp":1773954288664,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.thromres.2020.02.021","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T02:29:41Z","timestamp":1582770581000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Argatroban dosing requirements in extracorporeal life support and other critically ill populations"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-9768","authenticated-orcid":false,"given":"J. Spencer","family":"Dingman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E.","family":"Coba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"To","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.thromres.2020.02.021_bb0005","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1378\/chest.11-1396","article-title":"Introduction to drug pharmacokinetics in the critically ill patient","volume":"141","author":"Smith","year":"2012","journal-title":"Chest."},{"issue":"9","key":"10.1016\/j.thromres.2020.02.021_bb0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented Renal Clearance in Critically Ill Patients: A Systematic Review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"10.1016\/j.thromres.2020.02.021_bb0015","first-page":"17","article-title":"Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments","volume":"2","author":"B\u03cbdingen","year":"2014","journal-title":"Ther Adv Infect Dis."},{"issue":"2","key":"10.1016\/j.thromres.2020.02.021_bb0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.1882","article-title":"Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation","volume":"37","author":"Ha","year":"2017","journal-title":"Pharmacotherapy."},{"issue":"7","key":"10.1016\/j.thromres.2020.02.021_bb0025","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/CCM.0000000000000317","article-title":"The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens","volume":"42","author":"Jamal","year":"2014","journal-title":"Crit Care Med."},{"key":"10.1016\/j.thromres.2020.02.021_bb0030","unstructured":"Annich G, Lynch W, MacLaren G, et al. ECMO: Extracorporeal Cardiopulmonary Support in Critical Care (The \u201cRed Book\u201d). ELSO 4th Edition. Ann Arbor, MI, 2013."},{"key":"10.1016\/j.thromres.2020.02.021_bb0035","unstructured":"Extracorporeal Life Support Organization. ELSO Anticoagulation Guideline. Available at: https:\/\/www.elso.org\/Resources\/Guidelines.aspx."},{"issue":"1","key":"10.1016\/j.thromres.2020.02.021_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11239-017-1494-0","article-title":"Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations","volume":"44","author":"Bain","year":"2017","journal-title":"J Thromb Thrombolysis."},{"key":"10.1016\/j.thromres.2020.02.021_bb0045","doi-asserted-by":"crossref","unstructured":"Dzierba AL, Roberts R, Muir J, et al. Severe Thrombocytopenia in Adults with Severe Acute Respiratory Distress Syndrome: Impact of Extracorporeal Membrane Oxygenation Use. ASAIO J. 2016 Nov\/Dec;62(6):710\u2013714.","DOI":"10.1097\/MAT.0000000000000415"},{"issue":"1","key":"10.1016\/j.thromres.2020.02.021_bb0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13613-017-0302-5","article-title":"Efficacy and safety of argatroban in patients with acute respiratory distress syndrome and extracorporeal lung support","volume":"7","author":"Menk","year":"2017","journal-title":"Ann Intensive Care."},{"key":"10.1016\/j.thromres.2020.02.021_bb0055","doi-asserted-by":"crossref","unstructured":"Roug\u00e9 A1,2, Pelen F3,2, Durand M, et al. Argatroban for an alternative anticoagulant in HIT during ECMO. J Intensive Care. 2017 Jun 28;5:39.","DOI":"10.1186\/s40560-017-0235-y"},{"key":"10.1016\/j.thromres.2020.02.021_bb0060","unstructured":"Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012."},{"issue":"3","key":"10.1016\/j.thromres.2020.02.021_bb0065","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc9024","article-title":"Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study","volume":"14","author":"Saugel","year":"2010","journal-title":"Crit Care."},{"issue":"1","key":"10.1016\/j.thromres.2020.02.021_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1345\/aph.1L224","article-title":"Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia","volume":"43","author":"Keegan","year":"2009","journal-title":"Ann Pharmacother."},{"issue":"2","key":"10.1016\/j.thromres.2020.02.021_bb0075","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1345\/aph.1E480","article-title":"Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia","volume":"39","author":"Tang","year":"2005","journal-title":"Ann Pharmacother."},{"issue":"5","key":"10.1016\/j.thromres.2020.02.021_bb0080","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jtcvs.2007.01.008","article-title":"Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery","volume":"133","author":"Koster","year":"2007","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"1","key":"10.1016\/j.thromres.2020.02.021_bb0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/CCM.0b013e3181932394","article-title":"Argatroban for anticoagulation in continuous renal replacement therapy","volume":"37","author":"Link","year":"2009","journal-title":"Crit Care Med."},{"issue":"7","key":"10.1016\/j.thromres.2020.02.021_bb0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med."},{"issue":"11","key":"10.1016\/j.thromres.2020.02.021_bb0095","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit Care Med."},{"issue":"4","key":"10.1016\/j.thromres.2020.02.021_bb0100","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2020.02.021_bb0105","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2020.02.021_bb0110","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1592\/phco.29.9.1073","article-title":"Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients","volume":"29","author":"Smythe","year":"2009","journal-title":"Pharmacotherapy."},{"issue":"4","key":"10.1016\/j.thromres.2020.02.021_bb0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11239-012-0865-9","article-title":"Lower argatroban starting dose and lower aPTT goal range instead of aggressive monitoring","volume":"36","author":"Treschan","year":"2013","journal-title":"J Thromb Thrombolysis."},{"issue":"5","key":"10.1016\/j.thromres.2020.02.021_bb0120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1345\/aph.1H569","article-title":"Argatroban anticoagulation in critically ill patients","volume":"41","author":"Beiderlinden","year":"2007","journal-title":"Ann Pharmacother."},{"issue":"5","key":"10.1016\/j.thromres.2020.02.021_bb0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/0885066608321246","article-title":"Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure","volume":"23","author":"Begelman","year":"2008","journal-title":"J Intensive Care Med."},{"issue":"6","key":"10.1016\/j.thromres.2020.02.021_bb0130","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1594.2007.00388.x","article-title":"Argatroban in extracorporeal membrane oxygenation","volume":"31","author":"Beiderlinden","year":"2007","journal-title":"Artif Organs."},{"issue":"2","key":"10.1016\/j.thromres.2020.02.021_bb0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1051\/ject\/201749115","article-title":"Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Venovenous Hemofiltration","volume":"49","author":"Sin","year":"2017","journal-title":"J Extra Corpor Technol."},{"key":"10.1016\/j.thromres.2020.02.021_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-218179","article-title":"Acute oxygenator failure: A new presentation of heparin-induced thrombocytopenia in a patient undergoing venovenous extracorporeal membrane oxygenation support","author":"Ratzlaff","year":"2016","journal-title":"BMJ Case Rep."},{"issue":"4","key":"10.1016\/j.thromres.2020.02.021_bb0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MAT.0b013e31805c0d6c","article-title":"A case series describing the use of argatroban in patients on extracorporeal circulation","volume":"53","author":"Cornell","year":"2007","journal-title":"ASAIO J."},{"issue":"1","key":"10.1016\/j.thromres.2020.02.021_bb0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1399-6576.2008.01825.x","article-title":"Accuracy of Sequential Organ Failure Assessment (SOFA) scoring in clinical practice","volume":"53","author":"Tallgren","year":"2009","journal-title":"Acta Anaesthesiol Scand."},{"issue":"1","key":"10.1016\/j.thromres.2020.02.021_bb0155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/CCM.0000000000001375","article-title":"Validity of a Modified Sequential Organ Failure Assessment Score Using the Richmond Agitation-Sedation Scale","volume":"44","author":"Vasilevskis","year":"2016","journal-title":"Crit Care Med."},{"issue":"9","key":"10.1016\/j.thromres.2020.02.021_bb0160","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1097\/01.CCM.0000178178.02574.AB","article-title":"De keizer NF, Vroom MB, De jonge E. Reliability and accuracy of Sequential Organ Failure Assessment (SOFA) scoring","volume":"33","author":"Arts","year":"2005","journal-title":"Crit Care Med."},{"issue":"7","key":"10.1016\/j.thromres.2020.02.021_bb0165","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1007\/s00134-008-1039-2","article-title":"Influence of continuous veno-venous hemofiltration on argatroban clearance in a patient with septic shock","volume":"34","author":"Schusterschitz","year":"2008","journal-title":"Intensive Care Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820300682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820300682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:41:13Z","timestamp":1758735673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820300682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":33,"alternative-id":["S0049384820300682"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.02.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Argatroban dosing requirements in extracorporeal life support and other critically ill populations","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}